
"Drugs are such delicate mechanisms and drug development is so fraught with risk and uncertainty and the inherent complexity and the volatility of the pharma industry is constantly keeping us very busy."
Tags:
Eoin Vaughan, CEO of Mercury Engineering, and Dermot Gildea, Director of Life Sciences, highlight the key priorities of their exciting new Mercury 2021 strategy, the rationale behind their transition into…
Jean Delaney, pharma leader and partner at PwC Ireland, discusses the evolution she has seen in the pharma market, and more broadly in Ireland, during her extensive career at PwC.…
David Adlam, Regional Manager of Ireland and South West UK, and Paul Morris, Strategic Account Manager for Life Sciences at Agility, discuss the company’s increased commitment to Ireland, their ongoing…
See our Cookie Privacy Policy Here